To date, no broad-spectrum PDE4 inhibitor has shown clinical efficacy in CNS disorders without being limited by intolerable side effects or insufficient brain penetration.These challenges highlight the need for next-generation PDE4 inhibitors with improved brain penetration and tolerability. The gene discussed is PDE4A; the disease is central nervous system disorder.